Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
60 people get UCBJF.PK articles and Market Currents by email alert.
Get email alerts on UCBJF.PK »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
There are no Focus articles on UCBJF.PK.
To learn more about Seeking Alpha Pro, click here.
-
-
Rheumatoid Arthritis Slip-Up Unlikely To Affect Resurgent UCB SharesEP Vantage • Fri, Sep 28, 2012 -
-
-
-
-
Failure to Launch for Last Year's Big Pharma and Biotech HopesEP Vantage • Fri, Feb 13, 2009
-
Biotech Day In Review: BioSimilar Cancer Drug Enters TrialCentient Biotech Investor • Thu, Mar 22, 2007 -
-
Biotech Day in Review: ImClone Chooses to Go It AloneCentient Biotech Investor • Wed, Feb 7, 2007
There are no Transcripts on UCBJF.PK.
There are no News articles on UCBJF.PK.
UCBJF.PK vs. ETF Alternatives
Company Description
Currently, there's no company description for UCBJF.PK.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Wednesday, December 28, 2011, 3:02 AM Immunomedics (IMMU) and UCB (UCBJF.PK) tweak their pact for developing and marketing epratuzumab, a drug for lupus, cancer and other diseases. The changes predominately concern marketing rights. UCB also gets a five-year warrant to buy 1M Immunomedics shares at $8 apiece; IMMU currently at $3.37. Comment! [Healthcare]